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Prodromal Angina Limits Infarct Size in the Setting of Acute Anterior Myocardial Infarction
Treated With Primary Percutaneous Intervention
To the Editor: We demonstrated that prodromal angina reduces
infarct size in the setting of acute myocardial infarction (MI)
treated with fibrinolysis (1), and this favorably influences outcome
(2). Although the mechanism(s) remain unclear, we proposed a
role for ischemic preconditioning (1), while others suggested
accelerated thrombolysis (3). If preconditioning plays a role, the
effect should be detectable regardless of how the infarct-related
artery (IRA) reperfusion is achieved, and studying patients under-
going primary percutaneous intervention (pPCI) may elucidate
such role in determining myocardial protection.
Between January and August 1998, 22 patients were prospec-
tively and consecutively enrolled if they had: 1) chest pain duration
6 h; 2) ST-segment elevation of1 mm in two contiguous leads;
3) IRA Thrombolysis In Myocardial Infarction (TIMI) flow grade
0 to 1 at baseline angiography and achievement of TIMI flow
grade 3; 4) first acute anterior MI; and 5) new-onset prodromal
angina within the previous 24 h. Exclusion criteria were hemody-
namic instability or the presence of malignant arrhythmias. Symp-
tom status before MI was checked with a questionnaire filled in by
the admitting physician. A 12-lead electrocardiogram (ECG) was
recorded before and 30 min after angioplasty, then daily until
discharge. The sum of ST-segment elevation (ST1) was mea-
sured manually 20 ms after the end of QRS complex. Infarct size
was estimated from the 12-lead ECG according to a 32-point
QRS system score (4). On the admission ECG, all leads exhibiting
100-V ST1 received the maximum QRS score. The sum
(QRS0) represented the extent of the area at risk, while that at
seven days (QRS7) represented the actual MI size. The “ECG
salvage index” was calculated as (QRS0  QRS7)/QRS0. Blood
samples for measuring creatine kinase (CK)-MB levels were taken
on admission, and every 8 h for the first 24 h. The infarct size was
estimated on the basis of the area under the curve of the CK-MB
concentration plotted against time. Left ventriculography (30°
right anterior oblique) was taken on baseline, before any revascu-
larization therapy, and six months later. Ventricular volumes and
ejection fraction were calculated by the area-length method, and
regional wall motion analysis was performed with the centerline
method (5). The area-at-risk was defined as the number of chords
showing 2 standard deviations below the normal at the baseline,
while infarct size as the number of chords with the same feature at
Table 1. Clinical Characteristics, Angiographic Data, and Ischemia Time According to the
Presence of Prodromal Angina
Angina Negative
(n  10)
Angina Positive
(n  12) p Value
Age (yrs) 64  14 60  9 0.50
Gender (% male) 70 75 1.00
Smoking (%) 20 25 1.00
Hypertension (%) 32 45 0.37
Diabetes (%) 20 17 1.00
Hypercolesterolemia (%) 40 25 0.77
Previous angina 3 months (%) 40 33 1.00
Heart rate (beats/min) 79  9 77  12 0.62
SBP (mm Hg) 143  7 154  22 0.24
Killip class (1) 20 25 1.00
No. of vessel with 50% stenosis (% of
patients):
1-vessel disease 90 83 1.00
1-vessel disease 10 17 1.00
Collateral circulation to IRA 0 0 NA
Symptom onset to hospital arrival (min) 95 (68–165) 90 (71–136) 0.87
Hospital arrival to procedure initiation (min) 37 (27–45) 30 (19–37) 0.30
Procedure initiation to stable TIMI flow grade 3
re-establishment (min)
17 (15–19) 13 (6–15) 0.1
Total ischemia time (from symptom onset to
stable TIMI flow grade 3) (min)
145 (125–211) 130 (98–189) 0.30
Aspirin (%) 100 100 1.00
Unfractionated heparin 100 100 1.00
Coronary stenting (%) 100 100 1.00
Abciximab (%) 40 33 0.90
Thienopyridines 100 100 1.00
Beta-blockers 70 67 0.90
ACE inhibitors 80 83 0.82
ACE  angiotensin-converting enzyme; IRA  infarct-related artery; min  minutes (median and 25th to 75th interquartile
range); SBP  systolic blood pressure; TIMI  Thrombolysis In Myocardial Infarction.
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the six-month ventriculography. The “ventriculographic salvage
index” was defined as (area at risk  infarct size)/area at risk. The
primary end point was the reduction of ventriculographic infarct
size in patients with prodromal angina. Based on previous experi-
ence (2), to detect a 25% relative reduction of infarct size, 11
patients per group were necessary (alpha  0.05, beta  0.2). The
data are presented as mean values  standard deviation, if not
otherwise stated. Continuous variables were analyzed with an
unpaired t test and Mann-Whitney test. A value p  5% was
considered significant.
Twenty-two patients were studied; 12 (54.5%) with and 10
(45.5%) without prodromal angina. The clinical and angiographic
variables are listed in Table 1. There were no differences between
groups. Despite a similar QRS0 (14.6  2.2 vs. 13.4  2.3, p 
0.25), patients with prodromal angina had a smaller infarct size
(QRS7: 4.5  2.5 vs. 6.5  2.4, p  0.07), and a significantly
better salvage index (68  21% vs. 52  14%, p  0.05). The
average reduction of ST1 was similar (63  22% vs. 66  18%;
p  0.67). The area under the CKMB curve was smaller in the
prodromal angina group (3,557  2,541 vs. 6,005  2,965
U·l1·24 h, p  0.05). Due to very short time-to-treatment, both
groups improved ventriculographic parameters at follow-up, but
patients with prodromal angina showed an additional 32% of
myocardium at risk salvaged (95% confidence interval [CI]: 9% to
56%; p  0.01), and six-month ejection fraction significantly
improved (8%, 95% CI: 0.6% to 15%; p  0.036). Details are
reported in Table 2.
In this prospective study, the presence of prodromal angina
before an anterior MI successfully reperfused with pPCI protects
the ischemic myocardium, being associated with a smaller infarct
size. Lytic agents take 45 to 60 min to reestablish blood flow;
Andreotti et al. (3) reported in patients with MI preceded by
prodromal angina that fibrinolysis accelerates IRA reperfusion by
21 min causing smaller infarct size. Angioplasty is not affected by
a slow onset of action, and the presence of prodromal angina would
not be expected to affect the rapidity of reperfusion. We, therefore,
studied the protection afforded by prodromal angina on jeopar-
dized myocytes independent of the earlier dissolution of the
thrombus. Because both groups showed myocardial reperfusion, as
assessed by the concomitant presence of TIMI flow grade 3 and
significant reduction of ST1, and no other major baseline
clinical and angiographic differences were detected, our data
suggest that infarct size reduction is mainly driven by precondi-
tioning, when total occlusion time and reperfusion adequacy are
controlled for. However, prodromal angina patients achieved
TIMI flow grade 3 slightly earlier, suggesting that its presence
might have caused a more unstable clot structure, due to less
activated platelets, as supported by experimental data (6).
Table 2. Ventriculographic Data According to Presence of Prodromal Angina Before Index Event
Wall Motion
(SD/Chord)
Recovery
(%)
Area at Risk
(No. of Chords)
B
Infarct Size
(No. of Chords)
C
Salvage
Index
(%)
EF (%)
B C B C
PA present
1) 3.20 0.85 73 41 8 80 67 75
2) 3.70 3.07 17 58 43 26 46 55
3) 3.25 0.64 80 59 8 86 47 74
4) 3.62 0.19 95 51 5 90 34 74
5) 3.00 0.74 75 49 5 90 48 75
6) 2.86 2.55 11 44 25 43 53 59
7) 3.05 0.58 81 36 8 78 62 71
8) 3.58 2.91 81 52 35 33 44 56
9) 3.05 0.75 25 45 7 85 51 73
10) 3.52 0.13 96 46 6 87 40 72
11) 2.95 0.58 80 45 4 91 47 69
12) 2.65 2.49 9 40 30 25 51 59
Mean 3.20 1.28* 60† 47 15‡ 64§ 49 68
 SD 0.34 1.10 34 7 14 27 9 8
PA absent
1) 2.48 2.48 0 30 30 0 76 65
2) 3.26 2.11 35 55 14 75 55 65
3) 2.59 1.13 56 30 7 77 62 75
4) 3.91 2.67 32 67 45 33 26 54
5) 2.16 1.87 13 31 21 32 64 52
6) 2.65 2.48 6 34 30 22 66 55
7) 3.41 2.35 31 50 26 48 55 63
8) 2.80 1.40 50 35 21 41 52 67
9) 3.89 2.55 34 65 48 26 29 52
10) 2.56 2.07 19 35 30 14 60 51
Mean 2.97 2.11 28 43 27 32 55 60
 SD 0.60 0.51 18 15 13 26 16 8
*p  0.03 vs. follow-up wall motion abnormalities in patients without PA; †p  0.01 vs. percent recovery of patients without PA; ‡p  0.05 vs. infarct size in patients without
PA; §p  0.01 vs. salvage index in patients without PA; p  0.04 vs. six-month ejection fraction in patients without PA.
B  baseline ventriculography; C  control (i.e., six-month ventriculography); EF  ejection fraction; PA  prodromal angina.
1546 Correspondence JACC Vol. 45, No. 9, 2005
May 3, 2005:1545–53
Although prospective, our study reports a single-center
experience in a small and highly selected patient cohort with a
remarkably low-risk profile and a very short time-to-treatment.
There is a conflicting evidence about the prognostic significance
of prodromal angina associated with pPCI, because someone
found a better outcome (7), while others not (8,9). We
documented that the additional infarct size reduction associated
with prodromal angina translated into better long-term ejection
fraction, which could positively affect prognosis in an appropri-
ately sized patient cohort. Differences in patient selection and
study protocols (retrospective vs. prospective), as well as incon-
sistency of the prodromal angina definition, could also explain
conflicting results.
In conclusion, in our study, prodromal angina leads to a smaller
infarct size most likely through ischemic preconditioning. This
might represent a clinical “marker” of myocardial viability. Larger
prospective trials are needed to demonstrate whether this obser-
vation translates into a better outcome in patients receiving pPCI.
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Gender Differences in Endothelial Tissue-Type Plasminogen Activator Release
in Middle-Aged Adults
To the Editor: Between the ages of 45 and 65 years, the incidence
of myocardial infarction is three times higher in men compared
with women. In addition, the prevalence of thrombotic stroke is
50% greater in men than women (1). The mechanisms behind
this gender difference in atherothrombotic events remain unclear.
Impaired endothelial regulation of fibrinolysis, specifically reduced
capacity to release tissue-type plasminogen activator (t-PA), has
been linked directly to increased atheromatous plaque burden and
increased coronary atherothrombosis (2,3). Endothelial t-PA re-
lease is the predominant physiologic mechanism governing endog-
enous fibrinolysis. Currently, it is unknown if a gender difference
in endothelial t-PA release exists. If so, this may contribute to the
gender-related disparity in the prevalence and incidence of athero-
thrombotic events in middle-aged adults. We tested the hypothesis
that the capacity of the endothelium to release t-PA is greater in
middle-aged women compared with men.
Sixty-six healthy sedentary adult humans ages 45 to 65 years
were studied: 30 men (58  1 year) and 36 women (58  1 year).
All subjects were nonobese (body mass index 30 kg/m2), nor-
motensive (blood pressure 140/90 mm Hg), nonsmokers, non-
medicated, and free of overt cardiovascular, metabolic, and hema-
tologic disease, which were assessed by medical history, resting and
exercise electrocardiograms, and fasting blood chemistries. The
women were at least one year postmenopausal (range 1 to 32 years)
and had never taken or had discontinued use of hormone replace-
ment therapy at least one year before the start of the study. Before
participation, the subjects provided written informed consent
according to the guidelines of the University of Colorado at
Boulder.
Endothelial release of t-PA antigen and plasminogen activator
inhibitor (PAI)-1 antigen in response to bradykinin and sodium
nitroprusside was determined using an isolated forearm model.
Net release or uptake rates were calculated as follows: net release
(CV  CA)  (FBF  [101  hematocrit/100]), where CV and
CA represent the concentration in the vein and artery, respectively,
and FBF represents forearm blood flow. The total amount of t-PA
antigen released across the forearm in response to bradykinin was
calculated as the area under each curve above baseline using a
trapezoidal model. Bradykinin was infused intra-arterially at 12.5,
25, and 50 ng/100 ml tissue/min and sodium nitroprusside at 1, 2,
and 4 g/100 ml tissue/min for 5 min at each dose. To avoid an
order effect, the sequence of drug administration was randomized.
Plasma concentrations of t-PA and PAI-1 antigen were deter-
mined by enzyme immunoassay.
Differences in subject baseline characteristics and area under the
curve data were determined by unpaired t test. Group differences in
FBF and endothelial t-PA and PAI-1 release to bradykinin and
sodium nitroprusside were determined by repeated measures anal-
ysis of variance. The relationships among the variables of interest
were assessed by means of Pearson’s correlation coefficient and
linear regression analysis. Data are reported as mean  SEM.
Statistical significance was set at p  0.05.
Although none of the subjects was obese, the men demonstrated
higher (all p  0.05) body mass (81.8  1.5 kg vs. 65.4  1.6 kg),
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